Given their central roles in governing the excitability of these neuronal subtypes, functional modulation of Nav1.1 and Nav1.6 represents a promising therapeutic strategy to regulate hippocampal activity in early-stage AD, and their contributions to early-stage hyperactivity may prove critical to the development of disease-modifying AD therapeutics. This evidence concerns the gene SCN1A and Alzheimer disease.